Back to results
US 12,709,753 B2Granted
HIV immunotherapy with no pre-immunization step
AssigneeAmerican Gene Technologies International Inc.
InventorsHaishan Li, Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to immunotherapy for the treatment or prevention of HIV. In particular, the disclosure provides lentiviral vectors and associated methods that are optimized to treat HIV without a pre-immunization step.
Claims26
A method of treating cells, wherein the cells were isolated from a subject not previously immunized with an HIV-1 vaccine, the method comprising:
- (a) contacting peripheral blood mononuclear cells (PBMC) isolated from a subject infected with HIV-1 and not previously immunized with an HIV vaccine, with a therapeutically effective amount of a stimulatory agent, wherein the contacting is carried out ex vivo;
- (b) transducing, the PBMC ex vivo with a viral delivery system encoding at least one genetic element, wherein at least one genetic element comprises:
- a sequence having at least 95% sequence identity with SEQ ID NO:
- 31;
- or
- at least two of:
- (i) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 1, (ii) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 2, and (iii) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 3;
- or
- each of:
- (iv) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 97, (v) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 6, and (vi) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 7 and
- (c) culturing, or having cultured, the transduced PBMC for at least 1 day.
14 more elements
A method of treating HIV-1 infection in a subject not previously immunized with an HIV-1 vaccine, the method comprising:
- (a) removing leukocytes from the subject, wherein the subject was not previously immunized with an HIV-1 vaccine;
- (b) purifying peripheral blood mononuclear cells (PBMC) ex vivo from the leukocytes;
- (c) contacting the PBMC ex vivo with a therapeutically effective amount of a stimulatory agent;
- (d) transducing the PBMC ex vivo with a viral delivery system encoding at least one genetic element, wherein the at least one genetic element comprises:
- a sequence having at least 95% sequence identity with-SEQ ID NO;
- or
- at least two of:
- (i) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 1, (ii) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 2, and (iii) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 3;
- or
- each of:
- (iv) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 97, (v) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 6, and (vi) a sequence comprising at least 95% sequence identity with SEQ ID NO:
- 7;
- and
- (e) culturing, or having cultured, the transduced PBMC for at least 1 day.
16 more elements
Dependencies are inferred from the claim text.